Inspire Medical Systems, Inc. (NYSE:INSP) Shares Bought by Eversept Partners LP

Eversept Partners LP increased its stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 6.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 294,302 shares of the company's stock after purchasing an additional 18,032 shares during the quarter. Inspire Medical Systems makes up 4.8% of Eversept Partners LP's investment portfolio, making the stock its 4th largest holding. Eversept Partners LP owned about 0.98% of Inspire Medical Systems worth $54,558,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its holdings in shares of Inspire Medical Systems by 178.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company's stock valued at $66,000 after buying an additional 229 shares in the last quarter. Merit Financial Group LLC acquired a new stake in Inspire Medical Systems during the 4th quarter worth about $313,000. Jennison Associates LLC purchased a new position in Inspire Medical Systems during the 4th quarter valued at about $8,821,000. Janney Montgomery Scott LLC increased its holdings in shares of Inspire Medical Systems by 248.5% in the 4th quarter. Janney Montgomery Scott LLC now owns 4,806 shares of the company's stock valued at $891,000 after purchasing an additional 3,427 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at about $292,000. Institutional investors and hedge funds own 94.91% of the company's stock.

Inspire Medical Systems Stock Performance

Shares of INSP traded up $0.77 during trading hours on Friday, hitting $158.97. 315,939 shares of the company were exchanged, compared to its average volume of 583,830. The company has a market cap of $4.73 billion, a PE ratio of 91.89, a PEG ratio of 2.86 and a beta of 1.39. The firm's 50 day moving average is $162.86 and its 200-day moving average is $181.08. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $257.40.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. As a group, equities analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Robert W. Baird lowered their price objective on shares of Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 11th. Morgan Stanley lowered their price target on shares of Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating on the stock in a report on Tuesday, February 11th. Piper Sandler dropped their price target on shares of Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Wells Fargo & Company reduced their price objective on Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 11th. Finally, Stifel Nicolaus lowered their target price on Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research note on Monday, April 21st. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $218.90.

Insiders Place Their Bets

In related news, CTO John Rondoni sold 583 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the transaction, the chief technology officer now directly owns 10,424 shares in the company, valued at $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Randy Ban sold 25,584 shares of the company's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now owns 7,259 shares of the company's stock, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.10% of the company's stock.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.